{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:16:15Z","timestamp":1779279375940,"version":"3.51.4"},"reference-count":10,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2024,11,15]],"date-time":"2024-11-15T00:00:00Z","timestamp":1731628800000},"content-version":"unspecified","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Louis Feil Charitable Trust","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100017050","name":"Cycle for Survival","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100017050","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Nonna\u2019s Garden Foundation","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Allen and Frances Adler Clinical Scholar through Rockefeller University","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Louis Feil Charitable Trust","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"NIH","award":["K99-CA277591"],"award-info":[{"award-number":["K99-CA277591"]}]},{"name":"Henry R. Kravis Center for Molecular Oncology","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"Nonna\u2019s Garden Foundation, Louis Feil Charitable Trust","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"the National Center for Advancing Translational Sciences, National Institutes of Health","award":["UL1 TR001866"],"award-info":[{"award-number":["UL1 TR001866"]}]},{"name":"CCSG","award":["P30 CA08748"],"award-info":[{"award-number":["P30 CA08748"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,9,23]]},"published-print":{"date-parts":[[2024,11]]},"abstract":"<jats:p>Melanoma arising in association with a blue nevus (BN) is rare but has molecular similarities to uveal melanoma (UM), including GNAQ\/11 mutations. Tebentafusp was recently approved for UM based on improved overall survival in a phase 3 study. We hypothesized that tebentafusp may be active in BN-associated melanoma. Here, we present a case of metastatic BN-associated melanoma with rapid response and ~1\u2009year of disease control on tebentafusp. We also explore molecular and histological features of secondary resistance. Our case highlights that PD-1-resistant melanomas should be screened for GNAQ\/11 mutations, as tebentafusp may be a treatment option in this extremely rare disease.<\/jats:p>","DOI":"10.1136\/jitc-2024-009609","type":"journal-article","created":{"date-parts":[[2024,11,17]],"date-time":"2024-11-17T22:05:14Z","timestamp":1731881114000},"page":"e009609","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical benefit with tebentafusp in a patient with GNAQ mutant metastatic blue nevus-associated melanoma"],"prefix":"10.1136","volume":"12","author":[{"given":"Matthew R","family":"Kudelka","sequence":"first","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Rockefeller University, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison L","family":"Richards","sequence":"additional","affiliation":[{"name":"Marie-Jos\u00e9e and Henry R Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip","family":"Friedlander","sequence":"additional","affiliation":[{"name":"Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jedd D","family":"Wolchok","sequence":"additional","affiliation":[{"name":"Department of Medicine and Meyer Cancer Center, Weill Cornell Medicine, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea P","family":"Moy","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-4412","authenticated-orcid":false,"given":"Alexander N","family":"Shoushtari","sequence":"additional","affiliation":[{"name":"Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"Weill Cornell Medical College, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,11,17]]},"reference":[{"key":"2026052005000877000_12.11.e009609.1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18947"},{"key":"2026052005000877000_12.11.e009609.2","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/pcmr.12482","article-title":"Comparative analysis of the GNAQ, GNA11, SF3B1, and EIF1AX driver mutations in melanoma and across the cancer spectrum","volume":"29","author":"Johnson","year":"2016","journal-title":"Pigment Cell Melanoma Res"},{"key":"2026052005000877000_12.11.e009609.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-022-00714-1"},{"key":"2026052005000877000_12.11.e009609.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2103485"},{"key":"2026052005000877000_12.11.e009609.5","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1200\/JCO.21.01805","article-title":"Phase I Study of Safety, Tolerability, and Efficacy of Tebentafusp Using a Step-Up Dosing Regimen and Expansion in Patients With Metastatic Uveal Melanoma","volume":"40","author":"Carvajal","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026052005000877000_12.11.e009609.6","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006747","article-title":"Tebentafusp in combination with durvalumab and\/or tremelimumab in patients with metastatic cutaneous melanoma: a phase 1 study","volume":"11","author":"Hamid","year":"2023","journal-title":"J Immunother Cancer"},{"key":"2026052005000877000_12.11.e009609.7","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-009-0611-3"},{"key":"2026052005000877000_12.11.e009609.8","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.646"},{"key":"2026052005000877000_12.11.e009609.9","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7181\/acfs.2023.00024","article-title":"Malignant melanoma associated with a plaque-type blue nevus of the cheek: a case report","volume":"24","author":"Chung","year":"2023","journal-title":"Arch Craniofac Surg"},{"key":"2026052005000877000_12.11.e009609.10","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3549"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009609","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T12:00:29Z","timestamp":1779278429000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":10,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11,17]]},"published-print":{"date-parts":[[2024,11]]}},"alternative-id":["10.1136\/jitc-2024-009609"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009609","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11]]}}}